Katherine Rielly-Gauvin Sells 36,789 Shares of Liquidia (NASDAQ:LQDA) Stock

Liquidia Corporation (NASDAQ:LQDA) Director Katherine Rielly-Gauvin sold 36,789 shares of the business’s stock in a transaction that occurred on Wednesday, August 19th. The shares were sold at an average price of $74.99, for a total value of $2,758,807.11. Following the completion of the sale, the director owned 44,637 shares of the company’s stock, valued at $3,347,328.63. This trade represents a 45.18% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Katherine Rielly-Gauvin also recently made the following trade(s):

• On Thursday, August 20th, Katherine Rielly-Gauvin sold 18,393 shares of Liquidia stock. The stock was sold at an average price of $72.23, for a total value of $1,328,526.39.

Liquidia Trading Down 3.4%

Shares of NASDAQ:LQDA opened at $68.62 on Friday. The business’s 50 day moving average price is $79.29 and its 200-day moving average price is $56.21. Liquidia Corporation has a 1 year low of $21.15 and a 1 year high of $93.61. The firm has a market capitalization of $6.14 billion, a price-to-earnings ratio of 50.09 and a beta of 0.58. The company has a debt-to-equity ratio of 0.63, a current ratio of 2.31 and a quick ratio of 2.12.

Liquidia (NASDAQ:LQDA) last issued its quarterly earnings results on Wednesday, August 12th. The company reported $0.74 EPS for the quarter, missing the consensus estimate of $0.76 by ($0.02). The company had revenue of $171.68 million during the quarter, compared to analysts’ expectations of $168.48 million. Liquidia had a return on equity of 149.65% and a net margin of 30.74%.Liquidia’s revenue was up 1842.1% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.49) EPS. On average, equities research analysts forecast that Liquidia Corporation will post 2.57 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of analysts have recently commented on LQDA shares. Zacks Research cut shares of Liquidia from a “strong-buy” rating to a “hold” rating in a research note on Thursday, August 13th. BTIG Research lifted their price objective on Liquidia from $109.00 to $111.00 and gave the stock a “buy” rating in a report on Wednesday, August 12th. Oppenheimer set a $75.00 price objective on Liquidia in a research note on Friday, June 5th. Needham & Company LLC increased their target price on Liquidia from $70.00 to $110.00 and gave the company a “buy” rating in a report on Wednesday, August 12th. Finally, Lifesci Capital downgraded Liquidia from an “outperform” rating to a “hold” rating and set a $90.00 target price on the stock. in a research report on Wednesday, August 12th. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, three have issued a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, Liquidia has a consensus rating of “Hold” and a consensus price target of $98.08.

Institutional Investors Weigh In On Liquidia

A number of large investors have recently modified their holdings of the business. Seven Fleet Capital Management LP lifted its stake in shares of Liquidia by 25.2% in the second quarter. Seven Fleet Capital Management LP now owns 256,603 shares of the company’s stock worth $20,459,000 after buying an additional 51,727 shares in the last quarter. AXQ Capital LP purchased a new stake in Liquidia during the 2nd quarter valued at about $546,000. Nykredit A S purchased a new stake in Liquidia during the 2nd quarter valued at about $177,000. Globeflex Capital L P purchased a new stake in Liquidia during the 2nd quarter valued at about $175,000. Finally, Bank of New York Mellon Corp acquired a new stake in Liquidia in the 2nd quarter valued at about $29,694,000. Hedge funds and other institutional investors own 64.54% of the company’s stock.

Liquidia Company Profile

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).